HSBC Floats New Program
HSBC (NYSE:HSBC) today announced the launch of HSBC TradePay for Import Duties, a targeted financing solution for U.S. clients which simplifies the payment of import duties while optimizing working capital for businesses.Many corporates are currently facing changing working capital needs and increased upfront commitments. By settling payments of import duties directly and frictionlessly through HSBC TradePay, businesses can simultaneously access credit and complete payments, leading to more efficient settlement times and better visibility over cash flows.The solution is flexible and ensures import duty payments are made directly by HSBC, either through pre-agreed credit terms with brokers or direct ACH credits.Vivek Ramachandran, Head of Global Trade Solutions at HSBC said: “Clients’ working capital needs are evolving – and we’re responding swiftly with solutions that deliver the most value to them. “By settling import duties directly and frictionlessly through HSBC TradePay, our U.S. clients have more visibility and control over their working capital at the time they need it most. “As the world’s leading trade bank, we’re committed to supporting global businesses as a strategic partner and innovative problem solver, helping our clients navigate the complexities of global trade.”The HSBC TradePay platform utilizes innovative, digital solutions to help facilitate the transition away from paper-based operations, integrating financing and payments into one single journey.HSBC closed Tuesday at $56.62.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


